mspipeline

Added Ocrelizumab (R1594) (Roche/Genentech/Biogen) to phase 2.

The CUPID study of cannabinoids (currently on the list in phase 2) in the UK is:

- double-blind
- placebo-controlled
- multi-centre
- 3 years in duration
- and is aiming for enrollment of 500 people

I keep looking for some mention of what phase trial this is but can’t find any. So, if it looks like a duck, walks like a duck and quacks like a duck, I’m going to call it a duck…in this case, a phase 3 trial.

I removed A4I from the phase 2 list due to this page at clinicaltrials.gov.

I removed SGN-30 from the phase 1 list as Seattle Genetics no longer mentions multiple sclerosis anywhere on their website.

I deleted Neuren’s NNZ-2566 from phase 1 as the Neuren website makes no mention of MS trials, and they say:

Neuren’s strategy is to undertake clinical trials for acute conditions, which are generally shorter and less expensive than those for chronic conditions. This strategy provides the most cost-effective means of increasing shareholder value while controlling risk.

Neuren decides which targets to pursue and which compounds to develop only after consideration of the cost and complexity of trials, the ease with which results can be validated, and assessment of market need and commercial opportunity.

I removed Medarex’s MDX1100 from phase 1 because they are going forward with an ulcerative colitis trial, but the company’s website contains no mention of MDX1100 for MS that I could see.